Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Abstract
// Nicola J. Curtis 1 , Lorraine Mooney 1 , Lorna Hopcroft 2 , Filippos Michopoulos 1 , Nichola Whalley 2 , Haihong Zhong 3 , Clare Murray 4,6 , Armelle Logie 1 , Mitchell Revill 1 , Kate F. Byth 5 , Amanda D. Benjamin 4 , Mike A. Firth 1 , Stephen Green 1 , Paul D. Smith 2 and Susan E. Critchlow 2 1 iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK 2 iMED Oncology, AstraZeneca, Cambridge, UK 3 MedImmune, One MedImmune Way, Gaithersburg,...
Paper Details
Title
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Published Date
May 25, 2017
Journal
Volume
8
Issue
41
Pages
69219 - 69236
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History